AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

#CARTCELL

2 people · 2 posts

Heat trend for this story

Heat now 0·Peak in the comparable set 1 (Apr 19 02:00)·Change over 24h in the comparable set –·Participants now 1

Participants counted1

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

Records

Drug / trial	Readout	Setting
EGFRvIII CAR#CART #CARTCELL	13 patients: 2 PR, 7 SD	GBM · June plenary

Other cases in this chapter

autogene cevumeran7 of 8 responders alive at 4–6 years; 2 of 8 non-responders
CAR-PRISM20/20 MRD-negative; no progression at 15.3 mo median follow-up
mRNA-4157Melanoma RFS HR 0.44
局部 nivolumabOral pre-cancer clinical response 85%, 1-year clearance 82%

Floor

Apr 20Mon

Monday · 1 items

00:29
Blood Cancer Discovery@BCD_AACRScore6060
Don't miss Scientific Editor Carl June at his opening plenary talk on the evolution of #CARTcell therapy at #AACR26. This article explore...
Same topic #CARTCELL · 2 people #CELLTHERAPYHeat 54 likes0 replies1 repost

Apr 19Sun

Sunday · 1 items

01:35
Tanya Bondar@_TanyaBondar_Score6060
Excellent talk at #AACR26 by Matthew Frank overviewing many important developments in #CARTcell therapy for lymphoid malignancies
Same topic #CARTCELL · 2 people #STANDOMHeat 44 likes0 replies0 reposts